Heidelberg scientists decode the genetic foundations of rapid testicle evolution in mammals and humans. Evolutionary pressure across male mammals to guarantee the procreation of their own offspring led to a rapid evolution of the testicle.

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA – a prerequisite for protein synthesis in the cell. The poorly characterized factors are crucial to ensuring that the molecular machine responsible for splicing is working correctly. A research team has deciphered how the two cellular quality inspectors work.

Researchers from the University of Heidelberg have published a study on more than 60,000 patients in the renowned journal Lancet Digital Health, demonstrating the potential of AI in cardiac medicine.

Her ground-breaking research studies on the regulation of gene activity have earned Dr Angelika Feldmann the Hella Bühler Prize for 2026, which is endowed with 100,000 euros.

Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the ERC, which will support a project in the field of computational quantum chemistry. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola.

The two inter-university funding programs SEED4EU+ and 4EU+ Visiting Professorships are entering a new round of calls. With these programs, the 4EU+ European University Alliance pursues the goal of strengthening links between the eight partner universities, giving scope to new ideas and supporting inter-university projects.

Using a new combination of three sensors and artificial intelligence, researchers at Heidelberg Medical Faculty of Heidelberg University and Heidelberg University Hospital are recognising patterns in babies' movements that show whether their nervous system is developing healthily.

The German Research Foundation (DFG) is establishing new Collaborative Research Centres and extending existing research networks. Several DZHK sites are also involved. Particular emphasis is being placed on new research approaches to inflammation and thrombosis.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.

Professor Dr. Rohini Kuner from the Medical Faculty of Heidelberg University receives the Leibniz Prize of the German Research Foundation (DFG).

The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.

An Emmy Noether junior research group at Heidelberg University is investigating how to gain new insights into fundamental biological mechanisms from large-scale molecular data sets. Led by Junior Professor Dr Britta Velten, it has started work at the Centre for Organismal Studies and the Interdisciplinary Center for Scientific Computing.

This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.

The Medical Faculty Heidelberg of Heidelberg University and Mannheim University of Applied Sciences are combining their expertise in infectious disease research, mass spectrometry, and bioinformatics to overcome resistance in malaria vectors. The project is supported by funding from the Gates Foundation.

Tenderness can literally get under your skin: An international research group led by Heidelberg University's Medical Faculty and Heidelberg University Hospital has found that small skin wounds heal significantly faster in couples who are particularly affectionate with each other in everyday life and who also receive the hormone oxytocin. At the same time, they had lower stress levels.

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using a simple swab.

Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.

Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies.

Cells of the highly aggressive brain tumor glioblastoma exhibit predatory behavior: they exploit signaling between healthy neurons and internalize portions of their contact sites. Dr. Dr. Varun Venkataramani of the Heidelberg Medical Faculty of Heidelberg University, and his research team, will investigate how glioblastoma cells benefit from this process and whether it may represent a novel therapeutic target.

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

Heidelberg researchers identify local outbreak indicators and develop new regional modeling approach. The highly pathogenic avian influenza virus infection – commonly known as bird flu – primarily affects birds. Mammals, however, are also increasingly infected. This increases the probability that the virus will cross over to humans.

A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.